Cargando…

Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy

COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Glowinska, Irena, Labij-Reduta, Barbara, Juzwiuk, Jerzy, Lukaszewicz, Magdalena, Pietruczuk, Adam, Poplawska, Agata, Daniluk-Jamro, Anna, Kakareko, Katarzyna, Rydzewska-Rosolowska, Alicja, Naumnik, Beata, Koc-Zorawska, Ewa, Zorawski, Marcin, Hryszko, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457318/
https://www.ncbi.nlm.nih.gov/pubmed/36078913
http://dx.doi.org/10.3390/jcm11174984
_version_ 1784786025717956608
author Glowinska, Irena
Labij-Reduta, Barbara
Juzwiuk, Jerzy
Lukaszewicz, Magdalena
Pietruczuk, Adam
Poplawska, Agata
Daniluk-Jamro, Anna
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Naumnik, Beata
Koc-Zorawska, Ewa
Zorawski, Marcin
Hryszko, Tomasz
author_facet Glowinska, Irena
Labij-Reduta, Barbara
Juzwiuk, Jerzy
Lukaszewicz, Magdalena
Pietruczuk, Adam
Poplawska, Agata
Daniluk-Jamro, Anna
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Naumnik, Beata
Koc-Zorawska, Ewa
Zorawski, Marcin
Hryszko, Tomasz
author_sort Glowinska, Irena
collection PubMed
description COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccination. We performed a prospective longitudinal cohort study to determine longevity of the humoral response after SARS-CoV-2 vaccine. The study included 191 adult patients on hemodialysis and peritoneal dialysis. All participants had been vaccinated with three doses, either with BNT162b2 (Pfizer-BioNTech) (n = 109) or mRNA-1273 (Moderna) (n = 82). Anti-spike protein receptor-binding domain antibodies (anti-S IgG) were assessed using SARS-CoV-2 (RBD) IgG ELISA EIA-6150 IVD assay at baseline, on the 21st day and 43rd day, before a booster dose and two weeks thereafter. We found that before vaccination, 37.7% of the cohort had anti-S IgG titres concordant with seroconversion. After two-dose vaccination, seroconversion occurred in 97% of patients. The booster dose evoked a ~12-fold increase in antibody level. Obesity increased more than two-fold the odds for a decrease in anti-S IgG. Previous COVID-19 infection enhanced longevity of the humoral response following vaccination. In patients with previous COVID-19 infection, the BNT162b2 vaccine was associated with a higher odds of anti-S IgG waning compared to the mRNA-1273 vaccine. In conclusion, we report that obesity predisposes patients to protective antibody waning, hybrid immunity enhances odds for higher anti-S IgG concentrations and vaccine efficacy may be influenced by previous SARS-CoV-2 infection. The results might provide a rationale for vaccination protocol design.
format Online
Article
Text
id pubmed-9457318
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94573182022-09-09 Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy Glowinska, Irena Labij-Reduta, Barbara Juzwiuk, Jerzy Lukaszewicz, Magdalena Pietruczuk, Adam Poplawska, Agata Daniluk-Jamro, Anna Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Naumnik, Beata Koc-Zorawska, Ewa Zorawski, Marcin Hryszko, Tomasz J Clin Med Article COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccination. We performed a prospective longitudinal cohort study to determine longevity of the humoral response after SARS-CoV-2 vaccine. The study included 191 adult patients on hemodialysis and peritoneal dialysis. All participants had been vaccinated with three doses, either with BNT162b2 (Pfizer-BioNTech) (n = 109) or mRNA-1273 (Moderna) (n = 82). Anti-spike protein receptor-binding domain antibodies (anti-S IgG) were assessed using SARS-CoV-2 (RBD) IgG ELISA EIA-6150 IVD assay at baseline, on the 21st day and 43rd day, before a booster dose and two weeks thereafter. We found that before vaccination, 37.7% of the cohort had anti-S IgG titres concordant with seroconversion. After two-dose vaccination, seroconversion occurred in 97% of patients. The booster dose evoked a ~12-fold increase in antibody level. Obesity increased more than two-fold the odds for a decrease in anti-S IgG. Previous COVID-19 infection enhanced longevity of the humoral response following vaccination. In patients with previous COVID-19 infection, the BNT162b2 vaccine was associated with a higher odds of anti-S IgG waning compared to the mRNA-1273 vaccine. In conclusion, we report that obesity predisposes patients to protective antibody waning, hybrid immunity enhances odds for higher anti-S IgG concentrations and vaccine efficacy may be influenced by previous SARS-CoV-2 infection. The results might provide a rationale for vaccination protocol design. MDPI 2022-08-25 /pmc/articles/PMC9457318/ /pubmed/36078913 http://dx.doi.org/10.3390/jcm11174984 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Glowinska, Irena
Labij-Reduta, Barbara
Juzwiuk, Jerzy
Lukaszewicz, Magdalena
Pietruczuk, Adam
Poplawska, Agata
Daniluk-Jamro, Anna
Kakareko, Katarzyna
Rydzewska-Rosolowska, Alicja
Naumnik, Beata
Koc-Zorawska, Ewa
Zorawski, Marcin
Hryszko, Tomasz
Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title_full Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title_fullStr Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title_full_unstemmed Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title_short Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
title_sort factors influencing longevity of humoral response to sars-cov-2 vaccination in patients with end stage kidney disease receiving renal replacement therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457318/
https://www.ncbi.nlm.nih.gov/pubmed/36078913
http://dx.doi.org/10.3390/jcm11174984
work_keys_str_mv AT glowinskairena factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT labijredutabarbara factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT juzwiukjerzy factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT lukaszewiczmagdalena factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT pietruczukadam factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT poplawskaagata factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT danilukjamroanna factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT kakarekokatarzyna factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT rydzewskarosolowskaalicja factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT naumnikbeata factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT koczorawskaewa factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT zorawskimarcin factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy
AT hryszkotomasz factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy